Reuters: Regulatory News: Vical to stop developing melanoma therapy after trial failure

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

The Best Way to Manage your Money. Start using Mint today to set a budget, track your goals and do more with your money. From our sponsors

Vical to stop developing melanoma therapy after trial failure Aug 12th 2013, 10:16 Mon Aug 12, 2013 6:16am EDT Aug 12 (Reuters) - Vical Inc said it will stop developing its experimental cancer therapy Allovectin after a late-stage trial failed to show that the treatment was significantly better than chemotherapy. The company said it now planned to focus on its infectious disease vaccine programs. The trial tested Allovectin in patients with metastatic melanoma.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions